Stock Track | ImmunityBio Soars 5.11% After-Hours on Upcoming Business Update and FY2025 Financial Results Announcement

Stock Track02-28

ImmunityBio, Inc. (NASDAQ: IBRX) experienced a significant after-hours surge of 5.11% on Friday. The movement occurred in the post-market session, indicating strong investor interest following a company announcement.

The price movement appears to be a direct reaction to the company's announcement that it will host a live conference call to provide a comprehensive business update and review its financial results for the fiscal year ended December 31, 2025. The update is scheduled for the following Tuesday.

Investors are likely anticipating positive developments from this upcoming review, which will include progress across the company's clinical trial pipeline. ImmunityBio is a biotechnology firm focused on developing next-generation immunotherapies for cancer and infectious diseases, making clinical progress a key driver for investor sentiment.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1121764006?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-28 07:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1121764006","market":"hk","top_or_hot":-1,"title":"Stock Track | ImmunityBio Soars 5.11% After-Hours on Upcoming Business Update and FY2025 Financial Results Announcement","media":"Stock Track","content":"<p>ImmunityBio, Inc. (NASDAQ: IBRX) experienced a significant after-hours surge of 5.11% on Friday. The movement occurred in the post-market session, indicating strong investor interest following a company announcement.</p><p>The price movement appears to be a direct reaction to the company's announcement that it will host a live conference call to provide a comprehensive business update and review its financial results for the fiscal year ended December 31, 2025. The update is scheduled for the following Tuesday.</p><p>Investors are likely anticipating positive developments from this upcoming review, which will include progress across the company's clinical trial pipeline. ImmunityBio is a biotechnology firm focused on developing next-generation immunotherapies for cancer and infectious diseases, making clinical progress a key driver for investor sentiment.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | ImmunityBio Soars 5.11% After-Hours on Upcoming Business Update and FY2025 Financial Results Announcement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | ImmunityBio Soars 5.11% After-Hours on Upcoming Business Update and FY2025 Financial Results Announcement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-28 07:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ImmunityBio, Inc. (NASDAQ: IBRX) experienced a significant after-hours surge of 5.11% on Friday. The movement occurred in the post-market session, indicating strong investor interest following a company announcement.</p><p>The price movement appears to be a direct reaction to the company's announcement that it will host a live conference call to provide a comprehensive business update and review its financial results for the fiscal year ended December 31, 2025. The update is scheduled for the following Tuesday.</p><p>Investors are likely anticipating positive developments from this upcoming review, which will include progress across the company's clinical trial pipeline. ImmunityBio is a biotechnology firm focused on developing next-generation immunotherapies for cancer and infectious diseases, making clinical progress a key driver for investor sentiment.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IBRX","symbol_name":"ImmunityBio, Inc.","start_time":0,"source_url":"","article_id":"1121764006","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1121764006","pubTimestamp":1772235669,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"ImmunityBio, Inc. (NASDAQ: IBRX) experienced a significant after-hours surge of 5.11% on Friday. The movement occurred in the post-market session, indicating strong investor interest following a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IBRX":"ImmunityBio, Inc."},"translate_title":"个股追踪|ImmunityBio盘后飙升5.11%，因即将发布业务更新和2025财年财务业绩公告","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBRX":1},"content_text":"ImmunityBio, Inc. (NASDAQ: IBRX) experienced a significant after-hours surge of 5.11% on Friday. The movement occurred in the post-market session, indicating strong investor interest following a company announcement.The price movement appears to be a direct reaction to the company's announcement that it will host a live conference call to provide a comprehensive business update and review its financial results for the fiscal year ended December 31, 2025. The update is scheduled for the following Tuesday.Investors are likely anticipating positive developments from this upcoming review, which will include progress across the company's clinical trial pipeline. ImmunityBio is a biotechnology firm focused on developing next-generation immunotherapies for cancer and infectious diseases, making clinical progress a key driver for investor sentiment.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1121764006","isCrawlerRequest":true}